101 related articles for article (PubMed ID: 23834019)
1. Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review.
Grunnet M; Mau-Sørensen M; Brünner N
Scand J Gastroenterol; 2013 Aug; 48(8):899-905. PubMed ID: 23834019
[TBL] [Abstract][Full Text] [Related]
2. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma.
de Mingo M; Morán A; Sánchez-Pernaute A; Iniesta P; Díez-Valladares L; Pérez-Aguirre E; de Juan C; García-Aranda C; Díaz-López A; García-Botella A; Martín-Antona E; Benito M; Torres A; Balibrea JL
Hepatogastroenterology; 2007; 54(73):315-9. PubMed ID: 17419282
[TBL] [Abstract][Full Text] [Related]
3. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
4. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
5. Methylated TIMP-3 DNA in body fluids is an independent prognostic factor for gastric cancer.
Yu JL; Lv P; Han J; Zhu X; Hong LL; Zhu WY; Wang XB; Wu YC; Li P; Ling ZQ
Arch Pathol Lab Med; 2014 Nov; 138(11):1466-73. PubMed ID: 25357107
[TBL] [Abstract][Full Text] [Related]
6. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
Li L; Zhang S; Lin H; Lin JY
Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
8. TIMP-1 as a tumor marker in breast cancer--an update.
Würtz SO; Schrohl AS; Mouridsen H; Brünner N
Acta Oncol; 2008; 47(4):580-90. PubMed ID: 18465326
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
10. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
11. Tissue inhibitor of metalloproteinases-1 in breast cancer.
Würtz SØ; Schrohl AS; Sørensen NM; Lademann U; Christensen IJ; Mouridsen H; Brünner N
Endocr Relat Cancer; 2005 Jun; 12(2):215-27. PubMed ID: 15947098
[TBL] [Abstract][Full Text] [Related]
12. Expression of tissue inhibitors of metalloproteinase 1 (TIMP-1) in gastric cancer tissue.
Mroczko B; Lukaszewicz-Zajac M; Groblewska M; Czyzewska J; Gryko M; Guzińska-Ustymowicz K; Kemona A; Kedra B; Szmitkowski M
Folia Histochem Cytobiol; 2009 Jan; 47(3):511-6. PubMed ID: 20164040
[TBL] [Abstract][Full Text] [Related]
13. Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Miyagi Y
Gastric Cancer; 2006; 9(2):106-13. PubMed ID: 16767366
[TBL] [Abstract][Full Text] [Related]
14. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
15. Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.
Kuvaja P; Hulkkonen S; Pasanen I; Soini Y; Lehtonen S; Talvensaari-Mattila A; Pääkkö P; Kaakinen M; Autio-Harmainen H; Hurskainen T; Lehenkari P; Turpeenniemi-Hujanen T
Exp Cell Res; 2012 Jun; 318(10):1094-103. PubMed ID: 22465225
[TBL] [Abstract][Full Text] [Related]
16. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
17. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.
Li P; Qian J; Yu G; Chen Y; Liu K; Li J; Wang J
J Surg Oncol; 2012 Jan; 105(1):31-7. PubMed ID: 22161898
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.
Sharma R; Chattopadhyay TK; Mathur M; Ralhan R
Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792
[TBL] [Abstract][Full Text] [Related]
19. Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.
Frederiksen C; Lykke J; Christensen IJ; Brünner N; Nielsen HJ
Scand J Clin Lab Invest; 2007; 67(5):545-52. PubMed ID: 17763191
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Curran S; Dundas SR; Buxton J; Leeman MF; Ramsay R; Murray GI
Clin Cancer Res; 2004 Dec; 10(24):8229-34. PubMed ID: 15623598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
